Form 4: Director Ted Nark Reports Amneal Pharmaceuticals Equity Move

Director Ted Nark acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units and was granted 19,824 new units.

Summary

• Director Ted Nark exercised and settled 34,819 restricted stock units (RSUs) into Class A Common Stock on May 7, 2026.
• Following the transaction, the director holds 325,848 shares of Class A Common Stock.
• The director was also granted 19,824 new restricted stock units on May 6, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity vesting.

Positives

• Director maintains a significant equity stake of 325,848 shares, aligning interests with shareholders.

Negatives

• None identified.

Risks

• Future vesting of restricted stock units is subject to specific time-based conditions and annual meeting schedules.

Future Outlook

The newly granted 19,824 restricted stock units are scheduled to vest on the later of the day preceding the issuer's first annual meeting following the grant or the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that routine equity compensation and vesting for board members is standard practice in the pharmaceutical sector to ensure long-term retention and alignment with corporate performance.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity-based compensation of non-employee directors in the mid-cap pharmaceutical industry.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard director compensation.

Next Steps

• Vesting of the 19,824 newly granted restricted stock units subject to future performance or time-based criteria.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Insider Trading, Form 4, Restricted Stock Units, Director Ownership